JOP20240020A1 - مركبات تثبط الصورة المتماثلة ألفا لـ pi3k وطرق لعلاج السرطان - Google Patents
مركبات تثبط الصورة المتماثلة ألفا لـ pi3k وطرق لعلاج السرطانInfo
- Publication number
- JOP20240020A1 JOP20240020A1 JOJO/P/2024/0020A JOP20240020A JOP20240020A1 JO P20240020 A1 JOP20240020 A1 JO P20240020A1 JO P20240020 A JOP20240020 A JO P20240020A JO P20240020 A1 JOP20240020 A1 JO P20240020A1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- pi3k
- inhibit
- methods
- treating cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231156P | 2021-08-09 | 2021-08-09 | |
| PCT/US2022/039674 WO2023018636A1 (en) | 2021-08-09 | 2022-08-08 | Compounds that inhibit pi3k isoform alpha and methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20240020A1 true JOP20240020A1 (ar) | 2024-02-01 |
Family
ID=83188497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2024/0020A JOP20240020A1 (ar) | 2021-08-09 | 2024-02-01 | مركبات تثبط الصورة المتماثلة ألفا لـ pi3k وطرق لعلاج السرطان |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20240343728A1 (enExample) |
| EP (1) | EP4363414A1 (enExample) |
| JP (1) | JP2024533975A (enExample) |
| KR (1) | KR20240051953A (enExample) |
| CN (1) | CN118159534A (enExample) |
| AU (1) | AU2022325819A1 (enExample) |
| CA (1) | CA3227902A1 (enExample) |
| CL (1) | CL2024000327A1 (enExample) |
| CO (1) | CO2024000448A2 (enExample) |
| CR (1) | CR20240045A (enExample) |
| DO (1) | DOP2024000019A (enExample) |
| EC (1) | ECSP24008488A (enExample) |
| GE (1) | GEAP202416449A (enExample) |
| IL (1) | IL310588A (enExample) |
| JO (1) | JOP20240020A1 (enExample) |
| MA (1) | MA63885B1 (enExample) |
| MX (1) | MX2024000708A (enExample) |
| PE (1) | PE20240652A1 (enExample) |
| UA (1) | UA130857C2 (enExample) |
| WO (1) | WO2023018636A1 (enExample) |
| ZA (1) | ZA202401094B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025538147A (ja) | 2022-11-02 | 2025-11-26 | ペトラ・ファーマ・コーポレイション | 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化 |
| WO2024233256A1 (en) | 2023-05-05 | 2024-11-14 | Eli Lilly And Company | Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer |
| WO2025036439A1 (en) * | 2023-08-16 | 2025-02-20 | Laekna Pharmaceutical Ningbo Co., Ltd. | Multicyclic compounds and their use as pi3k alpha inhibitors |
| IL330261A (en) * | 2023-12-27 | 2026-08-01 | Genesis Molecular Ai Inc | Cancer treatment methods |
| WO2025201503A1 (en) * | 2024-03-28 | 2025-10-02 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2026060099A1 (en) * | 2024-09-12 | 2026-03-19 | Kymathera, Inc. | Selective pi3k inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0515025D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| WO2009001089A1 (en) * | 2007-06-26 | 2008-12-31 | Ucb Pharma S.A. | Fused thiazole derivatives as kinase inhibitors |
| CA2755285C (en) * | 2009-03-20 | 2014-02-11 | Yunxin Y. Bo | Inhibitors of pi3 kinase |
| DE102009043260A1 (de) * | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
| US9062055B2 (en) * | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| EA201692557A1 (ru) * | 2014-07-04 | 2017-05-31 | Люпин Лимитед | Хинолизиноновые производные в качестве ингибиторов pi3k |
| CN111909173B (zh) * | 2015-07-02 | 2025-03-04 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法 |
| WO2017221272A1 (en) * | 2016-06-23 | 2017-12-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of idelalisib |
| WO2021001431A1 (en) * | 2019-07-02 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer |
-
2022
- 2022-08-08 MA MA63885A patent/MA63885B1/fr unknown
- 2022-08-08 CN CN202280062281.6A patent/CN118159534A/zh active Pending
- 2022-08-08 CR CR20240045A patent/CR20240045A/es unknown
- 2022-08-08 UA UAA202400583A patent/UA130857C2/uk unknown
- 2022-08-08 GE GEAP202416449A patent/GEAP202416449A/en unknown
- 2022-08-08 EP EP22764505.8A patent/EP4363414A1/en active Pending
- 2022-08-08 KR KR1020247007455A patent/KR20240051953A/ko active Pending
- 2022-08-08 US US18/293,823 patent/US20240343728A1/en active Pending
- 2022-08-08 JP JP2024506896A patent/JP2024533975A/ja active Pending
- 2022-08-08 AU AU2022325819A patent/AU2022325819A1/en active Pending
- 2022-08-08 MX MX2024000708A patent/MX2024000708A/es unknown
- 2022-08-08 CA CA3227902A patent/CA3227902A1/en active Pending
- 2022-08-08 IL IL310588A patent/IL310588A/en unknown
- 2022-08-08 WO PCT/US2022/039674 patent/WO2023018636A1/en not_active Ceased
- 2022-08-08 PE PE2024000156A patent/PE20240652A1/es unknown
-
2024
- 2024-01-18 CO CONC2024/0000448A patent/CO2024000448A2/es unknown
- 2024-02-01 EC ECSENADI20248488A patent/ECSP24008488A/es unknown
- 2024-02-01 JO JOJO/P/2024/0020A patent/JOP20240020A1/ar unknown
- 2024-02-02 CL CL2024000327A patent/CL2024000327A1/es unknown
- 2024-02-02 ZA ZA2024/01094A patent/ZA202401094B/en unknown
- 2024-02-02 DO DO2024000019A patent/DOP2024000019A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024000327A1 (es) | 2024-08-09 |
| ZA202401094B (en) | 2025-05-28 |
| IL310588A (en) | 2024-04-01 |
| ECSP24008488A (es) | 2024-05-31 |
| EP4363414A1 (en) | 2024-05-08 |
| CN118159534A (zh) | 2024-06-07 |
| UA130857C2 (uk) | 2026-05-27 |
| CA3227902A1 (en) | 2023-02-16 |
| JP2024533975A (ja) | 2024-09-18 |
| CR20240045A (es) | 2024-02-20 |
| KR20240051953A (ko) | 2024-04-22 |
| PE20240652A1 (es) | 2024-04-04 |
| WO2023018636A1 (en) | 2023-02-16 |
| CO2024000448A2 (es) | 2024-02-15 |
| DOP2024000019A (es) | 2024-03-15 |
| MA63885B1 (fr) | 2025-01-31 |
| AU2022325819A1 (en) | 2024-02-29 |
| GEAP202416449A (en) | 2024-04-25 |
| MA63885A1 (fr) | 2024-09-30 |
| US20240343728A1 (en) | 2024-10-17 |
| MX2024000708A (es) | 2024-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230320A1 (ar) | مشتقات يوريا يمكن استخدامها لعلاج السرطان | |
| MA63885B1 (fr) | Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer | |
| JOP20250258A1 (ar) | مثبطات 2-آزا باي سيكلو هبتان kras | |
| MX2021005011A (es) | Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7). | |
| JOP20230218A1 (ar) | مشتقات بيرازولو بيريدين واستخداماتها | |
| MX2025012013A (es) | Protac de irak4 | |
| EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
| MA50013B1 (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
| SA523451700B1 (ar) | (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان | |
| JOP20220281A1 (ar) | مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها | |
| EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
| BR112021023110A2 (pt) | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton | |
| MX2025004073A (es) | Métodos para tratar el cáncer | |
| JOP20220235A1 (ar) | 3-فينوكسي أزيتيدين-1-يل بيرازينات مستبدلة لديها نشاط ناهض لـ gpr52 | |
| JOP20240022A1 (ar) | مركبات وتركيبات لعلاج حالات مرتبطة بنشاط sting | |
| MX2025004911A (es) | Terapia de combinacion para tratar el cancer | |
| MX2026002937A (es) | Nuevas fenilalquilaminas y su uso en el tratamiento de trastornos psiquiatricos | |
| BR112013025197A2 (pt) | métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer | |
| MX2022014888A (es) | Propanodioles mononitrosilados y bisnitrosilados para su uso terapéutico. | |
| GEAP202416416A (en) | Urea derivatives which can be used to treat cancer | |
| DE50211672D1 (de) | Urokinase-inhibitoren | |
| BR112021006424A2 (pt) | inibidores de quinase tyk2 | |
| UY39819A (es) | Métodos para tratar el cáncer | |
| BR112021009050A2 (pt) | combinação de um inibidor de mcl-1 e midostaurina, usos e composições farmacêuticas da mesma | |
| AR126147A1 (es) | Derivados de urea para tratar el cáncer |